Society guideline links: Management of symptoms and toxicities of anticancer therapy

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Cancer pain" and "Society guideline links: Neutropenic fever in adults with cancer".)

International

●Society for Immunotherapy of Cancer (SITC): Clinical practice guideline on immune checkpoint inhibitor-related adverse events (2021)

●Multinational Association of Supportive Care in Cancer (MASCC): Clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities (2020)

●MASCC: Clinical practice recommendations for the management of immune-mediated adverse events from checkpoint inhibitors (2020)

●MASCC: Clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors (2020)

●MASCC: Clinical practice recommendations for the management of immune-related adverse events – Pulmonary toxicity (2020)

●MASCC: Clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors (2020)

●MASCC: Clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors (2020)

●MASCC/International Society of Oral Oncology (ISOO): Clinical practice guidelines for the management of mucositis secondary to cancer therapy (2020)

●SITC: Clinical practice guideline on immune effector cell-related adverse events (2020)

Canada

●Cancer Care Ontario (CCO): Guidelines on management of dyspnea (breathlessness) in patients with cancer (2019)

●CCO: Clinical practice guideline for immune checkpoint inhibitor toxicity management (2018)

●CCO: Guidelines on management of nausea and vomiting and on loss of appetite, anorexia, and cachexia in cancer (2018)

●Canadian Cardiovascular Society (CCS): Guidelines for evaluation and management of cardiovascular complications of cancer therapy (2016)

●CCO: Guideline on interventions to address sexual problems in people with cancer (2016)

●A pan-Canadian practice guideline and algorithm – Screening, assessment, and supportive care of adults with cancer-related fatigue (2013)

●Canadian Working Group on Chemotherapy-Induced Diarrhea: Consensus statement on the prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer (2007)

United States

●Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors – Position article and guidelines (2021)

●Oncology Nursing Society (ONS): ONS Guidelines for cancer treatment-related skin toxicity (2020)

●American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH): Clinical practice guideline update for the management of cancer-associated anemia with erythropoiesis-stimulating agents (2019)

●American Society of Colon and Rectal Surgeons (ASCRS): Clinical practice guidelines for the treatment of chronic radiation proctitis (2018)

●ASCO: Clinical practice guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy (2018)

●Children's Oncology Group (COG): Guideline for the management of fatigue in children and adolescents with cancer and in pediatric recipients of hematopoietic stem-cell transplants (2018)

●COG: Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation (2016)

●Choosing Wisely: Don't administer supplemental oxygen to relieve dyspnea in patients with cancer who do not have hypoxia (2015)

●Choosing Wisely: Don't neglect to advise patients with cancer to get physical activity and exercise during and after treatment to manage fatigue and other symptoms (2015)

●Choosing Wisely: Don't use aloe vera on skin to prevent or treat radiodermatitis (2015)

●Choosing Wisely: Don't use L-carnitine/acetyl-L-carnitine supplements to prevent or treat symptoms of peripheral neuropathy in patients receiving chemotherapy for treatment of cancer (2015)

●Choosing Wisely: Don't use mixed medication mouthwash, commonly termed "magic mouthwash," to prevent or manage cancer treatment-induced oral mucositis (2015)

●American Heart Association (AHA): Scientific statement on long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy – Pathophysiology, course, monitoring, management, prevention, and research directions (2013)

Europe

●European Society of Medical Oncology (ESMO): Consensus recommendations for management of cardiac disease in cancer patients throughout oncological treatment (2020)

●ESMO: Clinical practice guidelines for the diagnosis, assessment and management of constipation in advanced cancer (2018)

●ESMO: Clinical practice guidelines for the management of anaemia and iron deficiency in patients with cancer (2018)

●ESMO: Clinical practice guidelines on diarrhoea in adult cancer patients (2018)

●ESMO: Clinical practice guidelines for the management of infusion reactions to systemic anticancer therapy (2017)

●ESMO: Clinical practice guidelines for the management of toxicities from immunotherapy (2017)

●European Society of Cardiology (ESC): Position paper on cancer treatments & cardiovascular toxicity (2016)

●ESMO: Clinical practice guidelines for the treatment of dyspnoea in advanced cancer patients (2015)

●ESMO-European Oncology Nursing Society (EONS): Clinical practice guidelines for the management of chemotherapy extravasation (2012)

●European Organization for Research and Treatment of Cancer (EORTC): Guidelines for the use of erythropoietic proteins in anaemic patients with cancer, 2006 update (published 2007)

●EORTC: New guidelines for the treatment of anaemia in patients with cancer – Implications for nursing practice (2006)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Interventional procedures guidance on biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer (2017)

●British Society of Gastroenterology (BSG): Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer (2011)